Biology Atlas

Map / Drugs

drug · intermediate · partly written

Comirnaty (BNT162b2)

Comirnaty is a nucleoside-modified mRNA vaccine in lipid nanoparticles that encodes the SARS-CoV-2 spike protein; in the pivotal trial it prevented 95 percent of symptomatic cases.

Also called: BNT162b2, Pfizer-BioNTech COVID-19 vaccine

This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.

The short version

Comirnaty is a lipid-nanoparticle mRNA vaccine that makes cells produce the SARS-CoV-2 spike protein so the immune system learns it. In a trial of 43,548 people, 8 cases occurred in the vaccine group and 162 in the placebo group, a reported efficacy of 95 percent. 1

Reported, not yet replicated

How it works more

The mRNA is carried in tiny fat particles that stop it being broken down too quickly. After injection into a muscle, some cells read the mRNA and temporarily make the spike protein, the immune system recognises it as foreign and makes antibodies and T cell responses, and the mRNA is broken down shortly afterwards. The trial paper describes it as a lipid nanoparticle-formulated, nucleoside-modified RNA that encodes a prefusion-stabilised, membrane-anchored full-length spike. A review identifies the modification as N1-methyl-pseudouridine. 2314

Established

The decisive trial more

In a multinational, placebo-controlled, observer-blinded trial, 43,548 people aged 16 or older were randomised 1:1 to two doses 21 days apart of the vaccine candidate (30 micrograms per dose) or placebo. Counting cases with onset at least 7 days after the second dose, there were 8 cases among those given the vaccine and 162 among those given placebo: 95 percent efficacy (95 percent credible interval 90.3 to 97.6). Of 10 severe cases after the first dose, 9 were in placebo recipients. Similar efficacy, generally 90 to 100 percent, was seen across age, sex, race, ethnicity, body mass index and coexisting conditions. The EMA page gives the vaccine-group count as 8 of 18,198 people without prior infection. Only the abstract was opened. 12

Reported, not yet replicated

Regulatory path more

The European Commission granted a conditional marketing authorisation on 21 December 2020, converted to a standard authorisation on 10 October 2022. In the US the product page lists the biologics licence reference STN 125742 and BioNTech Manufacturing GmbH as manufacturer; the date of the first US approval letter was not established. 235

Established

Safety as reported deep

The trial abstract reports short-term, mild-to-moderate pain at the injection site, fatigue and headache, with serious adverse events low and similar in the vaccine and placebo groups over a median of 2 months. EMA later recommended adding myocarditis and pericarditis to the product information as side effects (28 July 2021 entry); the frequency was not read. 13

Reported, not yet replicated

Modality

mRNA medicines and vaccines

Targets

Pathways

Indications

Identifiers

Code name

BNT162b2

Fda stn

125742

Trial

NCT04368728

Mechanism

Lipid nanoparticles carry nucleoside-modified mRNA encoding a prefusion-stabilised full-length spike; cells temporarily make the spike protein and the immune system makes antibodies and T cell responses against it. 124

Reported, not yet replicated

Delivery route

Must survive

Bare RNA is broken down quickly; the lipid particles protect it, and it must then enter muscle and immune cells and be translated. The modification is argued to help it escape innate sensing, which is a review argument not a trial result. 24

Reported, not yet replicated

Side effects

Injection-site pain, fatigue, headache

Short-term, mild-to-moderate in the pivotal trial; counts per symptom were not in the abstract. 1

Reported, not yet replicated

Serious adverse events

Low in incidence and similar between vaccine and placebo groups over a median of 2 months. 1

Reported, not yet replicated

Myocarditis and pericarditis

Added to the product information as side effects after a 28 July 2021 EMA recommendation; frequency not read. 3

Reported, not yet replicated

Verdict

Outcome

worked

Why

Randomised placebo-controlled efficacy of 95 percent (8 versus 162 cases) with a serious-adverse-event rate similar to placebo, followed by EU and US authorisation. 12354

Reported, not yet replicated

Teach this

In one sentence

Comirnaty is an mRNA vaccine in fat particles that makes the body briefly produce spike protein, and in the pivotal trial 8 vaccinated and 162 placebo recipients got symptomatic COVID-19. 12354

Reported, not yet replicated

The five-minute version

The vaccine is a modified mRNA recipe for the spike protein wrapped in lipid nanoparticles. Injected into the arm muscle, it is taken up by cells that briefly make spike, the immune system learns it, and the mRNA is broken down. In a trial of 43,548 people the vaccine group had 8 symptomatic cases and the placebo group 162. Short-lived injection-site pain, fatigue and headache were typical, and a later regulatory update added myocarditis and pericarditis. 12354

Reported, not yet replicated

What a listener will ask

Does the mRNA stay in the body?

EMA says it is broken down shortly after vaccination and that cells temporarily make the spike protein.

Why does it work better than CureVac CVnCoV?

Dose, RNA chemistry and variant era all differ and the trials did not isolate one; see the CVnCoV record.

Is 95 percent a guarantee?

It is an efficacy estimate from one trial under its case definition (cases from 7 days after dose 2) and period; it is not portable to other settings. 12354

Reported, not yet replicated

The common wrong idea

An mRNA vaccine permanently alters a person.

The regulator describes the mRNA as broken down shortly after vaccination, with cells making spike only temporarily (EMA).

The one citation to hand over: 1

Still open here

Not yet written: Assays used, Off targets.

Linked from

Sources

  1. Polack FP, Thomas SJ, Kitchin N, et al.. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383:2603-2615 (2020). paper; opened 2026-11-17 all records citing this
  2. European Medicines Agency. EMA recommends first COVID-19 vaccine for authorisation in the EU. EMA news page (2020). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  3. European Medicines Agency. Comirnaty: European public assessment report overview. EMA EPAR page (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  4. Morais P, Adachi H, Yu YT. The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines. Front Cell Dev Biol 9:789427 (2021). review; opened 2026-11-17 all records citing this
  5. US Food and Drug Administration. COMIRNATY (COVID-19 Vaccine, mRNA). FDA CBER product page (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
History of this record (5)

This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Year
2020
Regulatory status
approved
Status
partly written
Last updated
2026-11-19
Record
content/drugs/comirnaty.json